| First Author | Zimmermann C | Year | 2012 |
| Journal | Endocrinology | Volume | 153 |
| Issue | 11 | Pages | 5200-11 |
| PubMed ID | 22962258 | Mgi Jnum | J:191798 |
| Mgi Id | MGI:5463142 | Doi | 10.1210/en.2012-1490 |
| Citation | Zimmermann C, et al. (2012) Prevention of diabetes in db/db mice by dietary soy is independent of isoflavone levels. Endocrinology 153(11):5200-11 |
| abstractText | Recent evidence points towards the beneficial use of soy proteins and isoflavones to improve glucose control and slow the progression of type 2 diabetes. Here, we used diabetic db/db mice fed a high soy-containing diet (SD) or a casein soy-free diet to investigate the metabolic effects of soy and isoflavones consumption on glucose homeostasis, hepatic glucose production, and pancreatic islet function. Male db/db mice fed with a SD exhibited a robust reduction in hyperglycemia (50%), correlating with a reduction in hepatic glucose production and preserved pancreatic beta-cell function. The rapid decrease in fasting glucose levels resulted from an inhibition of gluconeogenesis and an increase in glycolysis in the liver of db/db mice. Soy consumption also prevented the loss of pancreatic beta-cell mass and thus improved glucose-stimulated insulin secretion (3-fold), which partly accounted for the overall improvements in glucose homeostasis. Comparison of SD effects on hyperglycemia with differing levels of isoflavones or with purified isoflavones indicate that the beneficial physiological effects of soy are not related to differences in their isoflavone content. Overall, these findings suggest that consumption of soy is beneficial for improving glucose homeostasis and delaying the progression of diabetes in the db/db mice but act independently of isoflavone concentration. |
